- Home
- ADIL vs BMRA Comparison
ADIL vs BMRA Comparison
Compare ADIL & BMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADIL | BMRA |
|---|---|---|
| Founded | 2010 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4M | 6.3M |
| IPO Year | 2017 | 1995 |
Fundamental Metrics
Financial Performance| Metric | ADIL | BMRA |
|---|---|---|
| Price | $1.89 | $2.10 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $37.50 | N/A |
| AVG Volume (30 Days) | ★ 95.4K | 17.1K |
| Earning Date | 03-06-2026 | 04-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $5,311,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.13 | $0.40 |
| 52 Week High | $3.67 | $4.60 |
Technical Indicators
Market Signals| Indicator | ADIL | BMRA |
|---|---|---|
| Relative Strength Index (RSI) | 49.67 | 48.34 |
| Support Level | $0.28 | $1.87 |
| Resistance Level | $3.67 | $2.23 |
| Average True Range (ATR) | 0.20 | 0.14 |
| MACD | -0.06 | 0.02 |
| Stochastic Oscillator | 45.95 | 64.25 |
Price Performance
Historical ComparisonAbout ADIL Adial Pharmaceuticals Inc
Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.
About BMRA Biomerica Inc.
Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.